Patent · US Active

High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions

US11857545B2 · kind B2 · utility

0Cited by
47References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 14, 2014
Grant dateJan 2, 2024
Priority date—
Expiry dateNov 14, 2034

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG05B2219/33192
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.